Photocure ASA (PHO.OL)
|Market Cap (Mil.):||kr470.65|
|Shares Outstanding (Mil.):||21.39|
* Q3 total revenues 56.8 million Norwegian crowns versus 19.2 million crowns
Aug 26 - Photocure ASA : * H1 sales revenues of Hexvix/Cysview NOK 43.2 million versus NOK 35.4 million * Q2 operating loss NOK 5.7 million versus loss NOK 13.9 million * Q2 sales revenues of Hexvix/Cysview NOK 23.8 million versus NOK 20.9 million * Q2 net loss NOK 4.2 million versus loss NOK 15.2 million * Source text for Eikon * Further company coverage
(Refiles to add a code for Salix Pharmaceuticals ) Aug 18 - Photocure ASA : * Says agreed to terminate the global licensing agreement for Lumacan with Salix Pharmaceuticals * Says Will receive a payment of US$ 5M from Salix and will regain the global rights and all intellectual property to Lumacan. * Source text for Eikon * Further company coverage
Earnings vs. Estimates
Analyst Research Reports
Photocure ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.